Study identification

PURI

https://redirect.ema.europa.eu/resource/14068

EU PAS number

EUPAS14067

Study ID

14068

Official title and acronym

IPF Italian observational study (FIBRONET)

DARWIN EU® study

No

Study countries

Italy

Study description

Long-term data on the natural course of IPF in Italy are scarce. Further, there is limited information on IPF in terms of patient characteristics and disease management. The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation. In particular, the study aims to provide information on disease characteristics and treatment modalities (at enrolment) and on disease progression, HRQoL and health care sector-related costs according to the Italian National Health Service (INHS) point of view (during 12 months of observation).

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Boehringer Ingelheim

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Italia S.p.A.
Regulatory

Was the study required by a regulatory body?

No